Detalles de la búsqueda
1.
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.
N Engl J Med
; 388(20): 1853-1862, 2023 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37195941
2.
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Rheumatology (Oxford)
; 63(4): 1058-1067, 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37449908
3.
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
J Rheumatol
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621793
4.
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Rheumatology (Oxford)
; 62(10): 3268-3279, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36727470
5.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Rheumatology (Oxford)
; 62(6): 2122-2129, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36282537
6.
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Mod Rheumatol
; 33(4): 668-679, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920102
7.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol
; 33(1): 64-72, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35365828
8.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Ann Rheum Dis
; 81(2): 184-192, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34740884
9.
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Ann Rheum Dis
; 81(3): 351-358, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34815219
10.
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Ann Rheum Dis
; 81(6): 815-822, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35241426
11.
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Rheumatology (Oxford)
; 61(3): 1035-1043, 2022 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34100922
12.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Rheumatology (Oxford)
; 61(12): 4797-4808, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35377447
13.
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
Rheumatol Int
; 42(2): 205-213, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34773130
14.
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
Ann Intern Med
; 174(11): 1510-1518, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34570596
15.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Mod Rheumatol
; 32(2): 263-272, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910188
16.
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
Ann Rheum Dis
; 80(4): 509-517, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33199274
17.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Ann Rheum Dis
; 80(7): 848-858, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33504485
18.
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Rheumatology (Oxford)
; 60(1): 256-262, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32699904
19.
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
Int J Clin Pract
; 75(12): e14975, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626502
20.
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 79(5): 595-604, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253184